Fig. 5.

GLP-1-Fc-FGF21 D1 has long-lasting reduced glucose and body weight gain in type 2 diabetic ob/ob mice with HFD-induced NASH. The diabetic mice were treated twice a week (day 0 and day 3) for 4 consecutive weeks via subcutaneous injection. (a) Blood glucose after first dosing was monitored (n=8) at different times. (b) Day 0 to day 3 Glucose AUC were calculated and shown. (c) Random blood glucose were monitored twice a week before each injection (n=8). (d) Fasting blood glucose was measured after the last dosing (n=8). (e) Body weight gain was measured twice a week (n=8). (f) Body weight was measured twice a week and is expressed as change from initial body weight (n=8). (g) Food intake was measured. (n=8). Data are shown as mean +/- standard deviation, Student's t-test was used for statistical analysis. *P<0.05; **P<0.01; ***P<0.001 (vs. control).